Lennart Brewitz

Lennart Brewitz

Auto-generated profile, based on publicly available information

Lennart Brewitz

Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
LBLennart Brewitz
Lennart Brewitz
LDLeo Dumjahn
Leo Dumjahn
YZYilin Zhao
Yilin Zhao
COC. David Owen
C. David Owen
SLStephen M. Laidlaw
Stephen M. Laidlaw
CSChristopher J. Schofield
Christopher J. Schofield
Nirmatrelvir (PF-07321332) is a nitrile-bearing small-molecule inhibitor that, in combination with ritonavir, is used to treat infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Nirmatrelvir interrupts the viral life cycle by inhibiting the SARS-CoV-2 main protease (Mpro), which is essential for processing viral polyproteins into functional nonstructural proteins. We report studies which reveal that derivatives of nirmatrelvir and other Mpro inhibitors with a nonactivated terminal alkyne group positioned similarly to the electrophilic nitrile of nirmatrelvir can efficiently inhibit isolated Mpro and SARS-CoV-2 replication in cells. Mass spectrometric and crystallographic evidence shows that the alkyne derivatives inhibit Mpro by apparent irreversible covalent reactions with the active site cysteine (Cys145), while the analogous nitriles react reversibly. The results highlight the potential for irreversible covalent inhibition of Mpro and other nucleophilic cysteine proteases by alkynes, which, in contrast to nitriles, can be functionalized at their terminal position to optimize inhibition and selectivity, as well as pharmacodynamic and pharmacokinetic properties.

22 May 2023 in Nature Chemistry
Verified
Journal Article
Open access
PDF file
TMTakashi Miura
Takashi Miura
TMTika R. Malla
Tika R. Malla
COC. David Owen
C. David Owen
ATAnthony Tumber
Anthony Tumber
LBLennart Brewitz
Lennart Brewitz
HSHiroaki Suga
Hiroaki Suga
γ-Amino acids can play important roles in the biological activities of natural products; however, the ribosomal incorporation of γ-amino acids into peptides is challenging. Here we report how a selection campaign employing a non-canonical peptide library containing cyclic γ2,4-amino acids resulted in the discovery of very potent inhibitors of the SARS-CoV-2 main protease (Mpro). Two kinds of cyclic γ2,4-amino acids, cis-3-aminocyclobutane carboxylic acid (γ1) and (1R,3S)-3-aminocyclopentane carboxylic acid (γ2), were ribosomally introduced into a library of thioether-macrocyclic peptides. One resultant potent Mpro inhibitor (half-maximal inhibitory concentration = 50 nM), GM4, comprising 13 residues with γ1 at the fourth position, manifests a 5.2 nM dissociation constant. An Mpro:GM4 complex crystal structure reveals the intact inhibitor spans the substrate binding cleft. The γ1 interacts with the S1′ catalytic subsite and contributes to a 12-fold increase in proteolytic stability compared to its alanine-substituted variant. Knowledge of interactions between GM4 and Mpro enabled production of a variant with a 5-fold increase in potency.

19 January 2021 in Chemical Communications
Verified
Journal Article
Open access
PDF file
TMTika R. Malla
Tika R. Malla
ATAnthony Tumber
Anthony Tumber
TJTobias John
Tobias John
LBLennart Brewitz
Lennart Brewitz
CSClaire Strain-Damerell
Claire Strain-Damerell
CSChristopher J. Schofield
Christopher J. Schofield
A high-throughput mass spectrometry based M pro assay identifies penicillin esters as new SARS-CoV-2 M pro inhibitors.

12 May 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TMTika R. Malla
Tika R. Malla
LBLennart Brewitz
Lennart Brewitz
DMDorian-Gabriel Muntean
Dorian-Gabriel Muntean
HAHiba Aslam
Hiba Aslam
COC. David Owen
C. David Owen
CSChristopher J. Schofield
Christopher J. Schofield
The SARS-CoV-2 main protease (Mpro) is a medicinal chemistry target for COVID-19 treatment. Given the clinical efficacy of β-lactams as inhibitors of bacterial nucleophilic enzymes, they are of interest as inhibitors of viral nucleophilic serine and cysteine proteases. We describe the synthesis of penicillin derivatives which are potent Mpro inhibitors and investigate their mechanism of inhibition using mass spectrometric and crystallographic analyses. The results suggest that β-lactams have considerable potential as Mpro inhibitors via a mechanism involving reaction with the nucleophilic cysteine to form a stable acyl-enzyme complex as shown by crystallographic analysis. The results highlight the potential for inhibition of viral proteases employing nucleophilic catalysis by β-lactams and related acylating agents.

10 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YNYu Nakashima
Yu Nakashima
LBLennart Brewitz
Lennart Brewitz
ATAnthony Tumber
Anthony Tumber
ESEidarus Salah
Eidarus Salah
CSChristopher J. Schofield
Christopher J. Schofield
2-Oxoglutarate (2OG) oxygenases are validated agrochemical and human drug targets. The potential for modulating their activity with 2OG derivatives has not been explored, possibly due to concerns regarding selectivity. We report proof-of-principle studies demonstrating selective enhancement or inhibition of 2OG oxygenase activity by 2-oxo acids. The human 2OG oxygenases studied, factor inhibiting hypoxia-inducible transcription factor HIF-α (FIH) and aspartate/asparagine-β-hydroxylase (AspH), catalyze C3 hydroxylations of Asp/Asn-residues. Of 35 tested 2OG derivatives, 10 enhance and 17 inhibit FIH activity. Comparison with results for AspH reveals that 2OG derivatives selectively enhance or inhibit FIH or AspH. Comparison of FIH structures complexed with 2OG derivatives to those for AspH provides insight into the basis of the observed selectivity. 2-Oxo acid derivatives have potential as drugs, for use in biomimetic catalysis, and in functional studies. The results suggest that the in vivo activity of 2OG oxygenases may be regulated by natural 2-oxo acids other than 2OG.

27 December 2021 in ChemMedChem
Verified
Journal Article
Open access
PDF file
STSiegfried T. D. Thun‐Hohenstein
Siegfried T. D. Thun‐Hohenstein
TSTimothy F. Suits
Timothy F. Suits
TMTika R. Malla
Tika R. Malla
ATAnthony Tumber
Anthony Tumber
LBLennart Brewitz
Lennart Brewitz
CSChristopher J. Schofield
Christopher J. Schofield
The reactive organoselenium compound ebselen is being investigated for treatment of coronavirus disease 2019 (COVID‐19) and other diseases. We report structure‐activity studies on sulfur analogues of ebselen with the Severe Acute Respiratory Syndrome coronavirus 2 (SARS‐CoV‐2) main protease (Mpro), employing turnover and protein‐observed mass spectrometry‐based assays. The results reveal scope for optimisation of ebselen/ebselen derivative‐ mediated inhibition of Mpro, particularly with respect to improved selectivity.